Bio4t2 is charting new paths in cancer therapeutics

Our technology unlocks CAR-T for solid tumors

Bio4t2 cancer therapeutics
Bio4t2 is overcoming the major barriers in targeting solid tumors with CAR-T.
Bio4t2 Car-T Barriers
PrismCore and Bio-Engine are showing promising clinical results in our first CAR-T product that targets overexpressed self-antigens on solid tumors.

Bi-CAR-T is on track for clinical application.

Bio4t2 LinkedIn
Bio4t2TM, PrismCoreTM, Bio-EngineTM and Bio-StrikeTM are trademarks of Bio4t2. Privacy Page »